

- Email: s.haldar@rbht.nhs.uk
-

¥,

Abstract

Background:

Results:

- HCP healthcare professional
- HR heart rate
- HRS heart rhythm society
- HRV heart rate variability
- ILR implantable loop recorder
- IQR interquartile range
- LSPAF long standing persistent atrial fibrillation
- mHealth mobile health
- NICE national institute for health and care excellence
- NPV negative predictive value
- PHE public health england
- PPG photoplethysmography
- PPV positive predictive value
- RADAR-base remote assessment of disease and relapses
- SD standard deviation

-
-
-
-
-
-

-
-

Clinical Perspectives

What is New?

Introduction

Page⁷

Hence, artificial intelligence (AI) systems have been programmed into wearable devices to 180 accurately predict and detect atrial arrhythmias from PPG waveforms.⁹

Study Design

The REMOTE-AF study is a single arm, dual-centre, clinical study (NCT05037136)

- exploring the validity of PPG recorded heart rate data being used in combination with
- accelerometer derived step count data to predict the recurrence of atrial arrythmias in a post
- ablation patient population. We labelled this combination as non-exercise related elevations

Page⁸

Study Participants

We remotely recruited thirty-five patients, and all provided informed consent. Six eligible participants who met the inclusion criteria (Table 1) declined to take part. Thirty-three patients had ILRs in situ; two patients had dual chamber pacemakers instead of ILRs. Each participant was fitted with a wearable device (Fitbit Charge 2) and provided with a smartphone (Samsung A2) at least 21 months after their index procedure. The remote assessment of disease and relapse (RADAR-base) data collection software and Fitbit mobile application was pre-installed onto the smartphone to allow seamless integration with the Fibit Charge 2 device sensors. The RADAR-base platform streamed data from the wearable, 228 mobile application and smartphone to a central location.¹⁶ This platform was installed on a

virtual machine hosted on Amazon Web Services (AWS) in the AWS Europe (London) region. Researchers were granted access to the Fitbit intraday developer application which allowed automated data collection for registered participants through the RADAR-base platform.

The A MEMS 3-axis accelerometer sensor enabled tracking of motion patterns and physical activity whilst the optical wrist-based PPG sensor allowed tracking of heart rate. Participants were encouraged to wear the wearable continuously, removing only during charging and exposure to water, and to connect the Bluetooth enabled smartphone to the internet at least once a day to allow synchronisation of data with the RADAR-base servers. At weekly intervals, participants were reminded via text message to synchronise data if uploads had not occurred and ad-hoc virtual meetings allowed troubleshooting of technical aspects. Participants were asked to report any adverse effects (skin irritation, health anxiety or stress) 242 related to the use of the wearable. Data was not collected beyond $31st$ January 2022. *Data Analysis* Heart rate and step count data recorded by the wearable were transmitted to the smartphone mobile application via Bluetooth. PPG recorded HR data underwent signal processing and was filtered for motion artefact using two accelerometer sensors. The RADAR-base application was programmed to allow access to the Fitbit developer intraday application and subsequently passively collected data and synchronised directly to a secure, encrypted cloud-

based web server. At the conclusion of the study, data was downloaded from the cloud server

- onto a local server for analysis. The data included heart rate and step count time series
- gathered from wearable devices and pooled at one-minute intervals. Mean heart rate data
- was calculated for each individual participant at one-minute intervals over the duration of

follow up. We developed a method to detect sequences potentially suggestive of atrial arrhythmia recurrence for each patient at thirty-minute overlapping intervals where heart rate 256 was at least two standard deviations (Z score \geq 2) above their mean for at least twenty minutes and later excluded those that were exercise related. We extracted all of the available tagged thirty-minute sequences for each patient (a total of 3208 sequences across our cohort) and associated within these sequences heart-rate data with step data counterparts at the same time points. Sequences were kept only where heart rate and step-count were both available for the duration of the thirty-minute window. Each of these sequences were then stratified into subcategories where corresponding step count values were denoted at 500 step intervals, with further sub categorisation based on heart rate delta change. We used a simple yet reliable method to identify time points where a participant's HR spiked. Across each sequence, we searched for the greatest increase in HR across a two-minute interval and recorded the size of that increase (in BPM). We termed this novel composite the "spike score". To compare across patients, we computed the normalised spike score (or spike z-score), which is this figure divided by the standard deviation of the patient's heart rate. We also computed the normalised downward spike score for each sequence, which is the largest two-minute decrease in a patient's heart rate that occurred after the upward spike. Normalised 271 spike scores \geq 0.75 were taken to be indicators of sudden and significant heart rate elevation. Each data sequence within each subcategory was compared to ILR data to denote if recurrence of an atrial arrythmia had occurred. For our analysis, a positive finding was recorded when our novel composite method for AF/AT recurrence correlated with ILR detected electrogram (EGM) episodes showing arrhythmia recurrence. If a text only episode of AF/AT was recorded by the ILR, we sought a

confirmatory EGM episode within a 24-hour period. ILR detected recurrences of atrial

significance level of 0.05. Missing data from the wearable, defined as lack of HR and step count data for the entire 30-minute duration of identified sequences using the method described above, were excluded from the extraction process and not included in final data analysis.

Results:

The mean [SD] age of recruited patients was 70.3 [+/-6.8] years with median 10 months [IQR 8-12] follow up (Table 2). Twenty-five patients completed at least six months follow up with eight of these patients completing the full 15 month follow up. In total, 236,871 hours of data were recorded via the wearable which amounts to a mean [SD] of 282 [+/-3.6] days per participant. On average, participants recorded data during 80.6% of daytime hours (8am and 8pm) and 71.1% of night-time hours (8pm-8am). Implantable loop recorder analysis showed 48.6% (17/35 patients) had recurrence of AF/AT. The average AF Quality of Life Survey 316 (AFEQT)¹⁷ score for patients in the non-AF/AT recurrence group was 48.9 at the beginning of the study and 32.3 at the end of the follow up period, an improvement of 20% compared to the AF/AT recurrence group who had scores of 45.0 pre study and 40.6 post study. Analysis of our data in a stepwise manner showed PPG- recorded HR correlating with AF/AT recurrence had a sensitivity of 95.3% (95%CI, 71-99); specificity 54.1% (95%CI, 50-59); PPV 15.8% (95%CI, 4-27); NPV 99.2% (95%CI, 99-100) and accuracy 57.4% (95%CI, 52-63) (Table 3). Combining PPG- recorded heart rate and step count with AF/AT recurrence yielded a sensitivity of 93.2% (95%CI,68–99%); specificity 54.9% (95%CI, 49-60%), PPV 19.1% (95%CI, 6-18%); NPV 98.6% (95%CI, 97-99%) and accuracy 58.7% (95%CI, 52- 65%) (Table 3) (Figure 2 and 3). PPG recorded HR sequences identified by a normalised 327 spike score of 0.75 or above over 2 minutes for both onset of heart rate ≥ 110 and cessation

- specificity 62.2% (95%CI, 56-69%); PPV 39.2% (95%CI, 24-54%); NPV 92.3% (95%CI,
- 89-96%) and accuracy 64.0% (95%CI, 56-71%) (Table 3) (Figure 4). Focused assessment of
- the latter in the AF/AT recurrence group as defined by ILR led to a sensitivity of 87.6
- (95%CI, 65-99%); specificity 68.3% (95%CI, 60-76%); PPV 53.6% (95%CI, 38-69%); NPV
- 93.0% (95%CI, 88-98%) and accuracy 74.0% (95%CI, 66-82%) (Table 3).
-

No adverse events such as skin irritation from wearable devices, health anxiety or stress were

reported by any of the 35 participants. Three wearable devices required strap replacement and

- resulted in 9 follow-up days lost.
-

Discussion:

REMOTE-AF evaluated the correlation between wearable device derived heart rate and

AF/AT recurrence. Current physician prescribed non-continuous rhythm monitoring tools

(ambulatory Holter monitors) which assess for arrhythmias at set time intervals are known to

have low detection yields.¹⁸ In symptomatic patients with suspected arrhythmias, a 24-hour

ambulatory Holter monitor has a diagnostic yield of 7% compared to 47% with a 7-day

345 monitor.¹⁹ At present, the gold standard for detection of atrial arrhythmias is continuous

monitoring via the implantable loop recorder (ILR). mHealth wearable devices can bridge the

gap between intermittent time limited Holter monitoring and invasive and costly ILR

monitoring.

To analyse our data, we adopted a stepwise approach to sequentially combine parameters

- from the wearable device. We saw an increase in PPV from 15.8% to 39.2% and
- improvement in accuracy from 57.4% to 64.0% when using our novel composite HR spike

 $P_{\text{age}}14$

score method compared to using PPG recorded HR alone to detect AF/AT recurrence. This is because, the spike score is more likely to represent true arrhythmia rather than physiological HR increase and hence more accurately differentiate between sinus tachycardia and pathological recurrences of AF/AT. In patients with known AF/AT recurrence as detected by ILR, our novel composite methodology utilising spike score resulted in the highest accuracy in identifying AF/AT recurrence in a post ablation cohort when compared with ILR. Irrespective of sequential improvements in accuracy, using this method results in 5 out of 10 episodes being misclassified as AF/AT. Further work with larger patient populations is needed to improve the diagnostic accuracy of our method. Our results yielded a high NPV and low PPV, likely due to our small sample size with low prevalence of AF/AT recurrence. In clinical practice, this supports the use of wearables in high risk patient populations with known diagnoses of atrial arrhythmias rather than for use in screening in low risk patient 365 populations (global AF prevalence of 0.51%).² Our results also show that our novel composite method in its current form, appropriately classifies non-recurrence of AF/AT but occasionally misclassifies recurrence. Within the current consumer market, the diversity in the accuracy and quality of PPG embedded in wearable devices limits the potential of 369 integrating these data safely into the clinician's decision-making process.^{5,20} Extensive research and funding has been dedicated to assessing the accuracy of PPG enabled wearables in detecting atrial arrhythmias, predominantly AF screening but there remains a lack of data in post AF intervention populations. Products developed by multi-billion-dollar global technology giants have shown promise that wearable devices could become a viable alternative in diagnosing and monitoring arrhythmias. The Apple Watch (Apple Inc, Cupertino, CA, USA), Fitbit (Google LLC, Mountain View, CA, USA) and Huawei Smartwatch (Huawei Technologies Co Ltd, Shenzhen, China) have been assessed in non-

randomised but large-scale prospective clinical trials, reporting accuracy of 95-97% in

378 detecting AF and modest positive predictive values (PPV). $21-23$

Our statistical analysis revealed a PPV significantly lower (Figure 5) than figures reported by these landmark PPG detected arrhythmia studies, however these large-scale studies were based on AF screening and not recurrence as in our cohort. Based on a recent meta-analysis, these figures are likely to be unrealistically elevated, therefore our results are likely to be 384 more representative of the accuracy of PPG in detecting AF/AT recurrence.⁶ Given there is 385 limited published data, predominantly case reports, $24-27$ documenting wearable use in rhythm monitoring after catheter ablation we are unable to make a direct comparison of PPG enabled wearables in this patient cohort. The reported clinical metric in the landmark studies only analysed PPG HR waveforms intermittently whilst stationary, with the majority at night. We reported results for all data both during active daytime hours and whilst ambulatory, where clinically significant arrhythmias are more likely. Overall, our data provides greater real-world analysis, and highlights the issue of lower diagnostic yields and challenges related to sensitivity and specificity of data from wearable devices during periods of activity. Conducting this study during a global pandemic also produced its own challenges but further advanced the necessity and accessibility for remote monitoring strategies, not just for western populations but worldwide, to ensure health equity.

Recurrence of paroxysmal and persistent atrial arrhythmias which are rate -controlled are likely to be misclassified as non-recurrence by our novel composite method. However, our NPV consistently being above 90% for all analysed groups shows that this had a minimal effect on our results. Our secondary endpoint showed that in patients with recurrence of atrial

also use the ILR as a comparator for PPG -detected AF from a wearable device, both a

smartwatch and smart ring. Data from this study can be used to further support or refute the 427 use of PPG based wearables to detect atrial arrhythmias.

429 Another study in progress is the SAFER (ISRCTN72104369)³² trial which will evaluate evidence to support the tolerability and feasibility of screening patients > 65 years old using PPG- enabled wearables. Our REMOTE-AF cohort with a mean age of 70.3 years and median follow up at 10 months, has already clearly demonstrated acceptability and tolerability in an older patient cohort. We recorded good compliance with device use and a roughly equal proportion of use during day-time and night-time hours. Alongside results 435 reported by the eBRAVE-AF trial $(NCT04250220)^{29}$ which screened for AF using smartphone PPG sensors, this leads to greater confidence that digital wearable technology can safely be used for not just screening but monitoring of known arrhythmia patients in the cohort at greatest risk of AF and its complications. Limited economic analyses demonstrate affordability and cost-savings associated with AF detection using wearables, specifically in over-65s, further highlighting their potential to improve health outcomes as measured by 441 quality-adjusted-life-years by enhancing primary and primordial prevention.^{33,34}

Incorporating heart rate variability (HRV) into our novel composite method would likely have further improved our PPV as significant changes to HRV have been shown to correlate 445 with $AF³⁵$ The Fitbit application programming interface (API) integrating HRV data was not open to researchers at the commencement of the study therefore REMOTE-AF study team did not have access to this data.

Future work requires more extensive investigation of PPG- enabled wearable devices and arrhythmia detection tools in real-world clinical settings with the design of larger trials

- synchronise in the past 7 days, however an automatic bi-weekly in-app notification would
- likely have increased adherence. A similar data upload issue was noted with the ILR. The
- Reveal LINQ™ device can store EGM data for 27 minutes of patient activated episodes and

476 30 minutes of automatic detected episodes, hence if multiple episodes are recorded over this time period without being downloaded to the base device, data is overwritten.

A further major limitation of the study was the small sample size and that all participants were Caucasian, potentially limiting the generalisability of our results. Sample size limitations prevented us from being able to power our study to derive statistical significance or draw wider conclusions applicable to a more diverse population. Given the exploratory nature of our study, our pilot data shows promise for further work to be undertaken with a sufficiently powered population size. Interruptions to ILR data upload via the CARELINK remote monitoring software is also acknowledged as a major limitation. Dependent on the frequency of arrhythmia recurrence, a more intensive download of ILR data would have been required to capture all EGM episodes of detected AF/AT recurrence (that are then able to be validated) rather than text only episodes. Our method of using text only episodes to confirm ILR detected AF/AT recurrence is likely to have affected the sensitivity of our results and is acknowledged as a significant limitation. In the two patients where we used pacemaker rhythm recording capabilities instead of ILR, we may have missed several episodes of AF/AT recurrence as episodes not documented on pacing reports at three monthly device interrogations had to be excluded. Furthermore, assessment of ILR EGMs was undertaken by a single reviewer therefore we recognise possible misclassifications may have occurred. Finally, the research team did not have access to raw PPG waveform or HRV data which possibly led to a lower PPV. Applying the normalised spike score to raw PPG waveforms or incorporating HRV data into our novel composite method may have led to improvements in PPV.

Conclusion:

Our novel composite of wearable device data (PPG recorded heart rate data, HR spike score

and step count) is a promising and modest predictor of AF/AT recurrence, in a post-ablation

cohort compared to the gold standard ILR. Further work is required to determine whether

consumer wearables integrating HR and step count with advanced algorithmic detection tools

can improve AF/AT detection and guide treatment strategies.

Acknowledgements:

We would like to thank the CASA-AF research team at the Royal Brompton and Harefield

Hospitals and the card*AI*c team at the University of Birmingham/University Hospitals

Birmingham NHS Foundation Trust for set up of the study, as well as Grace Augustine

(senior cardiac physiologist at Kettering General Hospital NHS Foundation Trust) for helping

with the validation using ILR. We would also like to thank Julia Kurps, Joris Borgdorff and

Nivethika Mahasivam at the Hyve (Utrecht, The Netherlands) for providing technology

support, the RADAR-base team (Richard Dobson, Amos Folarin, Yatharth Ranjan, Pauline

- Conde, Callum Stewart and Zulqarnain Rashid at King's College London, UK) and the
- BigData@Heart Consortium (Lead: Diederick E Grobbee, University Medical Centre
- Utrecht, The Netherlands; Scientific Coordinator: Folkert W Asselbergs, University of
- Amsterdam, The Netherlands).

Sources of Funding:

Disclosures:

- SG reports funding through the BigData@Heart Innovative Medicines Initiative [grant no.
- 116074]. AB reports funding from the BigData@Heart Innovative Medicines Initiative [grant
- no. 116074] during the conduct of the study. DK reports grants from the National Institute for
- Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK;
- NIHR132974 D2T-NeuroVascular; NIHR203326 BRC), the British Heart Foundation
- (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), the EU/EFPIA Innovative
- Medicines Initiative (BigData@Heart 116074), EU Horizon (HYPERMARKER 101095480),

- programme, and the European Society of Cardiology supported by educational grants from
- Boehringer Ingelheim/BMS-Pfizer Alliance/Bayer/Daiichi Sankyo/Boston Scientific, the
- NIHR/University of Oxford Biomedical Research Centre and British Heart
- Foundation/University of Birmingham Accelerator Award (STEEER-AF). In addition, he
- has received research grants and advisory board fees from Bayer, Amomed and Protherics
- Medicines Development; all outside the submitted work. GG reports support from the NIHR
- Birmingham Experimental Cancer Medicine Centre, NIHR Birmingham Surgical
- Reconstruction and Microbiology Research Centre, Nanocommons H2020-EU (731032), and
- the MRC Heath Data Research UK (HDRUK/CFC/01). SH reports speaker fees from
- Alivercor, consultancy fees from BMS, a research grant from Abbott and the NIHR grants
- (CASA and LOTO).
- GA, IKH, ZC, JJ, DJ, VM, WH and TW have no relevant disclosures.
-

References:

- 1. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al.
- 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed
- in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).

Eur Heart J 2021;42:373–498. doi:10.1093/eurheartj/ehaa612.

- 2. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An
- increasing epidemic and public health challenge. International Journal of Stroke
- 2021;16:217–221. doi:10.1177/1747493019897870.

- S, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society
- (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm
- Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the
- right tool for the right outcome,. EP Europace 2020;22:1147–1148.
- doi:10.1093/europace/euaa065.
- 11. Briosa e Gala A, Pope MT, Leo M, Lobban T, Betts TR. NICE atrial fibrillation
- guideline snubs wearable technology: a missed opportunity? Clin Med (Lond)

```
602 2022;22:77–82. doi:10.7861/clinmed.2021-0436.
```
- 12. Tudor-Locke C, Ducharme SW, Aguiar EJ, Schuna JM, Barreira T V., Moore CC, et
- al. Walking cadence (steps/min) and intensity in 41 to 60-year-old adults: the
- CADENCE-adults study. International Journal of Behavioral Nutrition and Physical Activity 2020;17:137. doi:10.1186/s12966-020-01045-z.
- 13. Wong T, Haldar SK. Long-term Outcomes in Long Standing Persistent Atrial
- Fibrillation (LoTO_CASA_AF) (Identifier NCT04280042). ClinicaltrialsGov 2020.
- https://clinicaltrials.gov/ct2/show/NCT04280042 (accessed September 22, 2022).
- 14. Haldar S, Khan HR, Boyalla V, Kralj-Hans I, Jones S, Lord J, et al. Catheter ablation
- vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation:
- CASA-AF randomized controlled trial. Eur Heart J 2020;41:4471–4480.
- doi:10.1093/eurheartj/ehaa658.
- 15. Sanders P, Pürerfellner H, Pokushalov E, Sarkar S, Di Bacco M, Maus B, et al.
- Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable
- cardiac monitor: Results from the Reveal LINQ Usability Study. Heart Rhythm
- 2016;13:1425–1430. doi:10.1016/j.hrthm.2016.03.005.

- 16. Ranjan Y, Rashid Z, Stewart C, Conde P, Begale M, Verbeeck D, et al. RADAR-Base:
- Open Source Mobile Health Platform for Collecting, Monitoring, and Analyzing Data
- Using Sensors, Wearables, and Mobile Devices. JMIR Mhealth Uhealth
- 2019;7:e11734. doi:10.2196/11734.
- 17. St. Jude Medical. The AF Effect on Quality of Life Survey (AFEQT). St Jude Medical,
- Inc 2023. /http://www.afeqt.org/ (accessed January 13, 2023).
- 18. Kotecha D, Breithardt G, Camm AJ, Lip GYH, Schotten U, Ahlsson A, et al.
- Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA
- Consensus Conference. EP Europace 2018;20:395–407. doi:10.1093/europace/eux318.
- 19. Chua S-K, Chen L-C, Lien L-M, Lo H-M, Liao Z-Y, Chao S-P, et al. Comparison of
- Arrhythmia Detection by 24-Hour Holter and 14-Day Continuous Electrocardiography
- Patch Monitoring. Acta Cardiol Sin 2020;36:251–259.
- doi:10.6515/ACS.202005_36(3).20190903A.
- 20. Xintarakou A, Sousonis V, Asvestas D, Vardas PE, Tzeis S. Remote Cardiac Rhythm
- Monitoring in the Era of Smart Wearables: Present Assets and Future Perspectives.
- Front Cardiovasc Med 2022;9. doi:10.3389/fcvm.2022.853614.
- 21. Perez M V., Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-
- Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. New England Journal
- of Medicine 2019;381:1909–1917. doi:10.1056/NEJMoa1901183.
- 22. Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, et al. Mobile
- Photoplethysmographic Technology to Detect Atrial Fibrillation. J Am Coll Cardiol
- 2019;74:2365–2375. doi:10.1016/j.jacc.2019.08.019.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.08.23289695;](https://doi.org/10.1101/2023.05.08.23289695) this version posted May 10, 2023. The copyright holder for this preprint

- 687 Sources of Inaccuracy in Photoplethysmography for Continuous Cardiovascular
- 688 Monitoring. Biosensors (Basel) 2021;11:126. doi:10.3390/bios11040126.
- 689 37. Chokesuwattanaskul R, Safadi AR, Ip R, Waraich HK, Hudson OM, Ip JH. Data
- 690 Transmission Delay in Medtronic Reveal LINQ Implantable Cardiac Monitor: Clinical
- 691 Experience in 520 Patients. J Biomed Sci Eng 2019;12:391–399.
- 692 doi:10.4236/jbise.2019.128030.
- 693 38. Gill SK, Karwath A, Uh H-W, Cardoso VR, Gu Z, Barsky A, et al. Artificial
- 694 intelligence to enhance clinical value across the spectrum of cardiovascular healthcare.
- 695 Eur Heart J 2023;44:713–725. doi:10.1093/eurheartj/ehac758.

696

 $\overline{7}$

697 **Tables:**

698 **Table 1: Inclusion and exclusion criteria for REMOTE-AF.**

699 LoTO in CASA LSPAF = Long term outcomes in long standing persistent atrial fibrillation RCT (ClinicalTrials.gov Identifier: NCT04280042). ILR = implantable loop recorder.

Table 2. Baseline characteristics of REMOTE-AF study participants

70

706 AF, atrial fibrillation; AFEQT, AF quality of life survey; BMI, body mass index; $CHA₂DS₂VASc$, congestive heart failure, high blood pressure, Age 75, Diabetes, previous Stroke or clot, Vascular disease, Age 65–74, Sex; HASBLED, hypertension; Abnormal liver/renal function, Stroke history, Bleeding history or predisposition, Labile INR (international normalized ratio), Elderly, Drug/alcohol usage; IQR, interquartile range; SD, standard deviation; TIA, transient ischaemic attack.

727

Table 3: Results table showing sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy for each stepwise combination of wearable device data.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.05.08.23289695;](https://doi.org/10.1101/2023.05.08.23289695) this version posted May 10, 2023. The copyright holder for this preprint

747 **Figures: Figure 1. Schematic showing the stepwise process undertaken for patients recruited to** 748 **REMOTE-AF.** 749 LoTO CASA LSAPF = Long-term outcomes in long standing persistent atrial fibrillation. PIS = Patient information sheet. $CF =$ Consent form. $AFEQT = AF$ quality of life survey. $RADAR =$ Remote assessment of diseases and relapses. 750 751 Participants identified from LoTO CASA LSPAF (ClinicalTrials.gov identifier: NCT04280042) with functioning implantable loop recorders 752 753 Telephone call made to identify those interested in taking part in the study 754 **Decline** 755 Agree to participate 756 Post PIS, CF and AFEQT 757 for consideration 758 OR Arrange hospital appointment Obtain verbal consent over the phone. sign CF Signed CF and completed AFEQT to be returned 759 Provide smartphone and wearable in the post. **Complete AFEQT** Post smart phone and wearable 760 Detailed written and verbal instructions provided on how to set up 761 and use the smartphone and wearable with RADAR-base phone application 762 Wearable data automatically transferred to smartphone application via Bluetooth and passively uploaded to secure server via RADARbase application 763 764 Weekly text reminders sent o participants with lack of data synchronisation for 7 days 765 Complete end of study AFEQT. Return and reset

smartphone and wearable

766

p_{age}32

803

804

805

806

Figure 5: Illustration to show sensitivity, specificity and PPV of smart devices in detecting recurrence of atrial arrhythmias in post intervention patient cohorts compared with gold standard ILR compared to our data.

827

828 **A.** REMOTE-AF data from 35 patients. **B.** ECG based detection post ablation in study of 99 patients.²⁴. C. Smart ring-based detection of atrial arrhythmia post DCCV in study of 35 patients.³⁰

- $ILR = *implantable* loop recorder. DCCV = *direct* current cardiovascular.$
- 829

